Division of Infective Dermatology, San Gallicano Dermatology Institute, Rome, Italy.
Dermatol Ther. 2012 Mar-Apr;25(2):214-8. doi: 10.1111/j.1529-8019.2012.01437.x.
The present prospective study was aimed at evaluating the long-term efficacy of local electrochemotherapy (ECT) with the intravenous administration of bleomycin, on disease progression and viral activity in classic Kaposi's sarcoma (cKS), a vascular tumor related to human herpes virus-8 infection. Eighteen patients affected by isolate or multiple cutaneous lesions, refractory to conventional treatments, although in the absence of visceral involvement, were enrolled in a study. Follow-up visits were performed after 4 weeks and every 6 months for up to 48 months. A more extensive exploration of the immunologic status as well as of virological parameters was performed in nine patients. The results showed a significant clinical improvement in all patients after 4 weeks. A complete regression was observed in 12 patients after the first ECT, while four patients required a second treatment on the residual lesions after 4 weeks from the first intervention. The positive outcome persisted during the subsequent clinical control visits. Two patients, that showed rapidly evolving did not improve and relapsed despite a second round of ECT treatment. Effective treatment was associated with the reduction of viral load to undetectable levels. These data support the conduct of larger studies directed at validating the efficacy of ECT as a first-line therapy for cKS.
本前瞻性研究旨在评估局部电化学疗法(ECT)联合博来霉素静脉给药在经典卡波西肉瘤(cKS)中的长期疗效,cKS 是一种与人类疱疹病毒 8 感染相关的血管肿瘤。18 例孤立或多发皮肤病变患者,尽管无内脏受累,但对常规治疗无效,入组本研究。每 4 周和每 6 个月进行随访,最长随访时间为 48 个月。对 9 例患者进行了更广泛的免疫状态和病毒学参数探索。结果显示,所有患者在 4 周后均有显著的临床改善。12 例患者在首次 ECT 后完全消退,4 例患者在首次干预后 4 周的残留病变上需要进行第二次治疗。随后的临床随访中,疗效持续存在。2 例病情迅速进展的患者尽管进行了第二轮 ECT 治疗,但仍未改善且复发。有效的治疗与病毒载量降低至不可检测水平有关。这些数据支持开展更大规模的研究,以验证 ECT 作为 cKS 一线治疗的疗效。